Business Wire

TX-TXONE-NETWORKS

31.1.2024 07:01:24 CET | Business Wire | Press release

Share
Ransomware-as-a-Service, Supply-chain Attacks, Geopolitical Issues Complicate OT/ICS Cybersecurity for Global Industries, TXOne Networks Report Reveals

TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, published its 2023 annual report detailing a growing range of cybersecurity issues facing global industries. The Crisis of Convergence: OT/ICS Cybersecurity 2023, which is publicly available for free download, details diverse intensifying challenges, including growth in attacks via Ransomware-as-a-Service (RaaS) models, exploitation of supply-chain vulnerabilities and prevalence of state-sponsored hackers and other politically motivated actors in the wake of geopolitical issues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130429836/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

TXOne Networks in September 2023 surveyed 405 key IT and OT security decision-makers from across multiple global markets and sectors including automotive, pharmaceuticals and biotechnology, chemical, general manufacturing, oil, and gas and transportation. The Crisis of Convergence: OT/ICS Cybersecurity 2023 distills the survey findings, alongside extensive TXOne Networks threat research from 545 cybersecurity incidents around the world in 2023.

“The threat landscape has intensified significantly in the industrial manufacturing and critical infrastructure sectors, leading to destructive events, economic losses, and potential risks to human safety...,” reads the TXOne Networks report, which was produced in collaboration with Frost & Sullivan. “Organizations emphasize the protection of critical OT (Operational Technology) assets as a top priority, with data security being a key investment area within their OT security budget allocations. ... Organizations are also seeking to invest in strengthening the resilience of their technological infrastructure and are turning to innovative approaches like Cyber-Physical Systems Detection and Response (CPSDR), which integrates OT expertise across various domains. This enhances OT security posture and resilience against evolving threats, enabling organizations to better protect their operations and ensure resilience in the face of a constantly changing threat environment.”

The Crisis of Convergence: OT/ICS Cybersecurity 2023 explores a range of topics relevant to contemporary OT/ICS cybersecurity:

  • Ransomware threats
  • OT system maintenance and Information Technology (IT) integration concerns
  • Nation-state cyberattacks and implications
  • Dedicated teams for OT and Industrial Control System (ICS) security management
  • OT/ICS cybersecurity investment
  • New regulations and standards propelling OT/ICS defense
  • Supply-chain Integrity

The Crisis of Convergence: OT/ICS Cybersecurity 2023 is the result of a thorough research and technical analysis that is aimed at delivering up-to-date insights into the global threat landscape and the tactics that malicious actors employ to launch attacks,” said Terence Liu, chief executive officer (CEO) of TXOne Networks. “The findings are clear. Organizations must move well beyond regulatory compliance in their OT/ICS cybersecurity strategies if they are to successfully adapt for the constantly evolving threat. Safeguarding the availability, reliability and security of revenue-generating operations will depend on new governance structures, enhanced team and technical capabilities, integration of advanced threat detection and response into cybersecurity frameworks and risk management across the supply chain.”

Download TXOne Networks’ The Crisis of Convergence: OT/ICS Cybersecurity 2023.

About TXOne Networks

TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130429836/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye